NEW ORLEANS, LA — The petrochemical plants stretch along the Mississippi River like a broken string of lights, from Baton Rouge down through St. Charles Parish and into Jefferson, each facility a chapter in Louisiana's industrial history. For generations of pipefitters, boilermakers, refinery workers, and shipyard laborers who built and maintained those plants, asbestos was simply part of the job. Decades later, many of those same workers are walking into oncology offices across the Gulf South with a diagnosis that carries the weight of every hour they spent in those facilities.
Ochsner Health's cancer program, anchored at its main campus in Jefferson, Louisiana, has become one of the primary destinations for mesothelioma patients across Louisiana, Mississippi, and the broader Gulf Coast region. Understanding what Ochsner offers, how its oncology infrastructure compares to nationally designated centers, and what options exist for patients who may need to travel or supplement their care is essential knowledge for anyone facing a mesothelioma diagnosis in this part of the country.
What Is the Ochsner Cancer Institute and What Does It Offer Mesothelioma Patients?
Ochsner Cancer Institute is the oncology division of Ochsner Health, one of the largest nonprofit health systems in the Gulf South, with its flagship campus at 1514 Jefferson Highway in New Orleans. The institute provides multidisciplinary cancer care across more than a dozen tumor types, including thoracic and pleural malignancies. For mesothelioma patients specifically, Ochsner's program includes thoracic surgery, medical oncology, pulmonology, and access to clinical research through its partnership infrastructure.
The institute is not currently a National Cancer Institute-designated cancer center, a distinction held by only 72 programs nationwide according to the NCI's cancer center registry. NCI designation signals that a center meets rigorous standards for research infrastructure, clinical trial availability, and specialized expertise. That doesn't mean Ochsner is without resources. Its thoracic oncology team treats pleural and peritoneal mesothelioma cases regularly, and the institution has affiliations and referral pathways that can connect patients to broader research networks when needed.
From an occupational health perspective, the geographic footprint Ochsner serves is critically important. Louisiana consistently ranks among the highest states for mesothelioma incidence, a direct consequence of its dense concentration of oil refineries, chemical plants, and shipbuilding operations that relied on asbestos insulation for much of the 20th century. According to data from the Centers for Disease Control and Prevention's National Institute for Occupational Safety and Health, mesothelioma mortality rates in states with heavy industrial and maritime histories run significantly above national averages. Ochsner's position in this region means its oncologists see mesothelioma cases with a frequency that builds genuine clinical experience.
Why the Gulf Coast's Industrial History Makes This Program So Relevant
Consider what the exposure data reveals about Louisiana's occupational landscape. The shipyards along the Mississippi River, the refineries from Norco to Geismar, the offshore platform fabrication yards in Morgan City: these were all environments where asbestos-containing insulation, pipe covering, gaskets, and fireproofing materials were used in enormous quantities from the 1940s through the early 1980s. Workers in these industries didn't just encounter asbestos occasionally. They breathed it daily, sometimes for decades.
The latency period for mesothelioma, typically 20 to 50 years between first exposure and diagnosis, means that workers who handled asbestos in the 1960s and 1970s are being diagnosed today. A 68-year-old retired boilermaker from Houma who spent his career maintaining refinery equipment is the archetypal patient walking into Ochsner's oncology program right now. He may have never heard the word mesothelioma until a chest X-ray revealed a suspicious pleural effusion, and he may have no idea that his occupational history is the direct cause of his illness.
For these patients and their families, proximity matters enormously. Mesothelioma treatment is intensive. It involves repeated appointments, imaging studies, chemotherapy infusions, and in some cases surgery. Having a capable oncology program within driving distance rather than requiring weekly flights to Houston or Boston can be the difference between a patient who engages fully with treatment and one who quietly disengages because the logistics are overwhelming.
"From an occupational health perspective, the communities along Louisiana's industrial corridor have paid an enormous price for the country's energy infrastructure, and they deserve specialized cancer care close to home," said Anna Jackson, an occupational health advocate who has worked with mesothelioma patients across the Gulf South.
How Does Ochsner's Approach Compare to NCI-Designated Centers?
This is a question every mesothelioma patient in Louisiana should be asking directly. NCI-designated centers, including the nearest options like MD Anderson Cancer Center in Houston and the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, offer something Ochsner currently cannot: guaranteed access to the most current clinical trials, disease-specific multidisciplinary tumor boards with mesothelioma subspecialty focus, and research programs that are actively generating new knowledge about this disease.
The CheckMate 743 trial, whose results were published in The Lancet and the New England Journal of Medicine, demonstrated that first-line nivolumab plus ipilimumab immunotherapy improved overall survival compared to chemotherapy in patients with unresectable pleural mesothelioma. That combination is now a standard-of-care option. But the next generation of trials, testing CAR-T cell therapies targeting mesothelin, novel checkpoint inhibitor combinations, and intraperitoneal chemotherapy approaches for peritoneal mesothelioma, are primarily running at NCI-designated centers and major academic medical systems.
A 2022 study published in the Journal of Clinical Oncology examined Phase I results for mesothelin-targeted CAR-T cell therapy in mesothelioma patients, finding signals of anti-tumor activity that have advanced the field toward further trials. Access to studies like that one is concentrated at a small number of institutions. Ochsner's oncology team can offer current standard-of-care treatment, including the nivolumab-ipilimumab combination for eligible patients, but patients who want to explore experimental protocols may need to travel.
What Ochsner does offer is a practical advantage: a large, established health system with multiple locations across Louisiana and Mississippi, robust imaging infrastructure, experienced surgical teams, and the ability to coordinate care across specialties in a single network. For a patient whose primary goal is high-quality standard-of-care treatment close to home, that's a meaningful set of capabilities.
The Treatment Landscape: What Current Evidence Supports
Understanding what evidence-based mesothelioma treatment looks like in 2026 helps patients evaluate any program, including Ochsner's.
For pleural mesothelioma, the current standard first-line options include nivolumab plus ipilimumab (based on CheckMate 743 data showing a median overall survival of 18.1 months compared to 14.1 months for chemotherapy) and platinum-based chemotherapy with pemetrexed for patients who aren't candidates for immunotherapy. Surgery, either extrapleural pneumonectomy or pleurectomy with decortication, remains an option for carefully selected patients with early-stage disease at high-volume centers.
For peritoneal mesothelioma, cytoreductive surgery combined with heated intraperitoneal chemotherapy (HIPEC) has shown striking results at specialized centers. Research published in the Journal of Clinical Oncology on cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal mesothelioma demonstrated five-year survival rates that far exceed what systemic chemotherapy alone achieves. This procedure requires a highly specialized surgical team and is not available at most community hospitals or regional cancer centers. Patients with peritoneal mesothelioma in Louisiana should specifically inquire whether Ochsner's surgical team performs HIPEC or whether referral to a center with that capability is appropriate.
Workers in these industries who receive a mesothelioma diagnosis should also understand that lung cancer and mesothelioma are distinct diseases with different biology, staging systems, and treatment approaches, even though both can arise from asbestos exposure. Getting the correct diagnosis and the correct disease-specific treatment plan is foundational.
What Patients and Families Should Do After a Mesothelioma Diagnosis
A diagnosis at Ochsner, or anywhere in the Gulf South, should trigger several parallel actions simultaneously. Treatment decisions cannot wait, but neither can the legal and financial steps that protect a patient's family.
First, confirm the diagnosis pathologically. Mesothelioma can be difficult to distinguish from adenocarcinoma and other malignancies on imaging alone. A tissue biopsy with immunohistochemical staining, interpreted by a pathologist experienced with mesothelioma, is essential. If there's any doubt, request a second pathology opinion from a high-volume center.
Second, request a complete occupational history review with your oncologist. The specific industries and job sites where you were exposed to asbestos matter for your legal case and may also inform your treatment planning, since exposure patterns correlate with mesothelioma subtype and location. The CDC's NIOSH mesothelioma data program tracks exactly these patterns and has documented the elevated risk across Louisiana's industrial sectors.
Third, consult with a mesothelioma-specialized attorney. Louisiana workers and their families may be entitled to compensation through asbestos trust funds, which were established by bankrupt asbestos manufacturers and collectively hold billions of dollars for claimants. The compensation process has strict timelines. Louisiana's statute of limitations for mesothelioma claims is one year from diagnosis, one of the shortest in the country. Use the statute of limitations tool to understand your specific deadline, and consult the lawyer directory to find attorneys with specific mesothelioma experience.
Fourth, ask Ochsner's oncology team directly about clinical trial eligibility. Even if the institution isn't running a mesothelioma-specific trial, oncologists at established cancer programs can often facilitate referrals or co-management arrangements with NCI-designated centers. You should not have to choose between local convenience and access to emerging treatments. A good oncologist will help you navigate both.
The compensation estimator tool can also help families understand the range of financial recovery available based on diagnosis type, exposure history, and jurisdiction. For more detailed guidance, the answers and compensation resource provides a comprehensive overview of the legal options available to mesothelioma patients and their families.
The Broader Occupational Health Picture Across the Gulf South
What the exposure data reveals most starkly is that Louisiana's mesothelioma burden isn't an accident of geography. It's the predictable result of decades of industrial expansion that used asbestos as a cost-effective fire retardant and insulator without adequately protecting the workers who installed and maintained it. The petrochemical corridor between Baton Rouge and New Orleans, sometimes called Cancer Alley for its concentration of industrial facilities, has generated occupational disease cases that will continue to appear in oncology offices for years to come.
The same pattern holds across the broader Gulf South. Mississippi shipyards, Alabama steel mills, Texas refineries, and Florida naval installations all share this legacy. Many patients from those states also seek care at Ochsner because of its regional reputation and accessibility.
From an occupational health perspective, the critical issue is that workers and their families often don't connect a decades-old job to a current cancer diagnosis. A retired pipefitter who left the refinery in 1988 may not spontaneously tell his oncologist about his asbestos exposure history. Oncologists at institutions like Ochsner who see high volumes of mesothelioma patients often have the occupational history instinct that community physicians may lack, which is one of the underappreciated advantages of seeking care at a regionally experienced cancer program.
Ochsner isn't the only option, and it shouldn't always be the final destination for every patient. But for the Gulf South worker who spent a career in the facilities that built this country's energy infrastructure, it represents an accessible, experienced starting point in a disease where getting to the right care quickly is everything.
Frequently Asked Questions
Does Ochsner Cancer Institute specialize in mesothelioma?
Ochsner's thoracic oncology program treats mesothelioma patients regularly given Louisiana's high incidence rates tied to its industrial history. However, Ochsner is not an NCI-designated cancer center, which means access to cutting-edge clinical trials may be more limited than at major academic centers like MD Anderson. Patients should ask specifically about mesothelioma case volume and clinical trial availability when consulting with the team.
What is the closest NCI-designated cancer center to Louisiana for mesothelioma?
MD Anderson Cancer Center in Houston, Texas, is the nearest NCI-designated comprehensive cancer center with a robust mesothelioma program. It is approximately a five-hour drive from New Orleans. The UNC Lineberger Comprehensive Cancer Center in Chapel Hill also has a dedicated thoracic oncology program, though it is considerably farther for most Louisiana patients, according to the NCI's cancer center registry.
What are the current standard treatments for pleural mesothelioma?
According to data published in The Lancet and the New England Journal of Medicine from the CheckMate 743 trial, first-line nivolumab plus ipilimumab immunotherapy now represents a standard option for unresectable pleural mesothelioma, showing improved overall survival compared to chemotherapy. Platinum-based chemotherapy with pemetrexed remains an alternative, and surgery is considered for select early-stage patients at high-volume centers.
How long do Louisiana mesothelioma patients have to file a legal claim?
Louisiana has a one-year statute of limitations for mesothelioma claims, measured from the date of diagnosis. This is one of the shortest filing windows in the United States. Missing this deadline can permanently bar recovery. Patients and families should consult with a mesothelioma-specialized attorney immediately after diagnosis. Use the statute of limitations tool at mesothelioma-lung-cancer.org to verify your specific situation.
Can mesothelioma patients at Ochsner access asbestos trust fund compensation?
Yes. Mesothelioma patients treated at any institution, including Ochsner, can pursue asbestos trust fund claims independently of where they receive medical care. More than 60 asbestos trust funds exist with collective assets in the billions of dollars, established by manufacturers who filed for bankruptcy due to asbestos liability. Compensation through these funds does not require a lawsuit and can often be pursued simultaneously with litigation against solvent defendants.
What is HIPEC and is it available for peritoneal mesothelioma patients at Ochsner?
HIPEC, or heated intraperitoneal chemotherapy, is a surgical procedure used for peritoneal mesothelioma in which chemotherapy is administered directly into the abdominal cavity at elevated temperatures following cytoreductive surgery. Research published in the Journal of Clinical Oncology has shown significantly improved outcomes for eligible patients. Patients should ask Ochsner's surgical team directly whether this procedure is performed at their facility or whether referral is recommended.
What industries in Louisiana carry the highest mesothelioma risk?
According to the CDC's NIOSH occupational cancer data, workers in oil refining, petrochemical processing, shipbuilding, construction, pipefitting, and boilermaking carry elevated mesothelioma risk due to historical asbestos use in those industries. Louisiana's concentration of these sectors along the Mississippi River corridor and Gulf Coast has produced mesothelioma incidence rates that consistently exceed national averages.
This article is for informational purposes only and does not constitute medical advice. Consult your healthcare provider for guidance specific to your situation.
Comments (3)